A Study of LY3314814 in Participants With Liver Impairment

Status:	Withdrawn
Conditions:	Gastrointestinal
Therapuetic Areas:	Gastroenterology
Healthy:	No
Age Range:	18 - 85
Updated:	6/30/2018
Start Date:	June 2018
End Date:	December 2018

Pharmacokinetics of LY3314814 in Subjects With Hepatic Impairment

The purpose of the study is to determine whether LY3314814 can be safely prescribed in
participants with liver impairment without a dose adjustment. Participants will be on study
for 11 days with follow-up about 7 days afterward.

Inclusion Criteria:

- Have a Body Mass Index (BMI) of 18 to 40 kilogram per meter square (kg/m²), inclusive, at
the time of screening

Exclusion Criteria:

- Have a history of or current significant ophthalmic disease, particularly any eye
problem involving the retina

- Have moderate or severe vitiligo or any other clinically significant disorder of skin
or hair pigmentation

- Have acute unstable neuropsychiatric disease

- Have active or uncontrolled neurologic disease, or clinically significant head injury

We found this trial at

sites

Orlando Clinical Research Center

5055 South Orange Ave Orlando FL 32909
Orlando, Florida 32806

407-240-7878